The estimated Net Worth of Trent A. Basarsky is at least $505 Tisíc dollars as of 27 April 2022. Dr Basarsky owns over 5,000 units of 908 Devices stock worth over $279,200 and over the last 4 years he sold MASS stock worth over $226,200.
Dr has made over 14 trades of the 908 Devices stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of MASS stock worth $8,750 on 27 April 2022.
The largest trade he's ever made was exercising 42,000 units of 908 Devices stock on 23 June 2021 worth over $73,500. On average, Dr trades about 16,533 units every 33 days since 2020. As of 27 April 2022 he still owns at least 80,000 units of 908 Devices stock.
You can see the complete history of Dr Basarsky stock trades at the bottom of the page.
Dr. Trent A. Basarsky Ph.D. is the VP of Corp. Devel. at 908 Devices.
Dr D is 53, he's been the VP of Corp. Devel. of 908 Devices since . There are 1 older and 4 younger executives at 908 Devices. The oldest executive at 908 Devices Inc. is Michael S. Turner Esq., J.D., 54, who is the VP, Sec. & Gen. Counsel.
Trent's mailing address filed with the SEC is C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON, MA, 02210.
Over the last 4 years, insiders at 908 Devices have traded over $16,182,689 worth of 908 Devices stock and bought 826,585 units worth $15,798,345 . The most active insiders traders include Keith Crandell, Kevin J. Knopp a E Kevin Hrusovsky. On average, 908 Devices executives and independent directors trade stock every 10 days with the average trade being worth of $64,663. The most recent stock trade was executed by Christopher D. Brown on 7 August 2024, trading 6,328 units of MASS stock currently worth $9,998.
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
908 Devices executives and other stock owners filed with the SEC include: